In case of tumor progress, the combination of PARP-inhibitors like Olaparib with Pembrolizumab could be a promising therapeutic approach considering the detected PALB2 mutation in this case because response to PARP inhibition has already been reported for PALB2-mutated breast cancer (59). Here, PALB2 is linked to breast cancer.